Susan Rienow

Experienced global pharmaceutical marketing leader with 13 years in the industry & a track record of accomplishment in roles of increasing responsibility.

I am known for being able to jump into new situations & successfully align a team around a common vision, and am comfortable leading in diverse situations, including cross-functional, multi-cultural & virtual teams.

Consistent success across multiple therapeutic areas (from primary care blockbuster brands to rare disease biologics) and geographies, including the US, Europe & Emerging Markets.

Expertise in global launches, strategic and analytical thinking & change management. Demonstrated high degree of learning agility & ability to thrive in complex environments.

Marie-Andrée Gamache

Marie-Andrée Gamache is Country President of Novartis UK and Ireland. She has spent over 20 years in the pharmaceutical industry, in a wide range of leadership roles at country, regional and global levels, across Europe, North America and Emerging Markets. Throughout her career, her priorities have seen her focus on helping create the right environment for better access to innovative medicines for patients, whilst also developing teams and company culture.

Originally from Montreal, Canada, Marie-Andrée joined Novartis in 2004, where she held a variety of roles in Sales and Brand Management, including in the UK. Marie-Andrée then served as Hematology Franchise Head, Belgium and Luxembourg, for three years. In 2015, she gained General Manager experience at Merck Serono both at a country and regional level, before returning to Novartis in 2019, where she was most recently the Head of Middle East and Africa, Novartis Oncology.

As Country President of Novartis UK and Ireland, Marie-Andrée is focused on creating an organisation with enhanced patient and customer focus, in order to build bold partnerships with the NHS; improving access to treatments for patients and supporting the healthcare systems to build back better post-pandemic.

Antonio Payano

Antonio has been Chief Executive Officer for Bayer UK & Ireland since September 2021. In this time, he has been elected as co-Vice-Chair of the European Medicines Group.

Antonio has had a succession of local, regional and global roles with Bayer over the past 25 years. Before coming to the UK, he was Head of Region Eastern Europe/Middle East and Head of Global Healthcare Programs where he had a lead role in negotiations for PhRMA

Middle East and Africa in several countries throughout the region and led cross-industry delegations with governments and non-profit foundations in lower-middle-income countries. He also has in-depth experience of working collaboratively as part in-country trade associations in the Czech Republic and Slovakia.

Bayer’s portfolio and future pipeline extends across primary and secondary care, including specialised commissioning products, so Antonio is well attuned to many of the issues faced by others along the development, access and adoption pathway

Away from work, Antonio lives in London and is married with two daughters.

Tim Ringrose

Tim trained as a nephrologist and intensive care doctor in Oxford and is CEO of Cognitant Group, a company on a mission to empower people with information about their health and treatment options. He is current president of the Digital Health section at the Royal Society of Medicine, a non-executive director and adviser for several health tech companies and a mentor for the NHS clinical entrepreneur programme.

Sheuli Porkess

Dr Sheuli Porkess is the Vice-President of the Faculty of Pharmaceutical Medicine and the Founder and Chief Medical Officer of Actaros Consultancy.

Sheuli’s career began in clinical medicine in the NHS before moving to industry and working medicine development, medical affairs and research policy within the UK and internationally, across multiple therapy areas. Sheuli has been working on COVID since the start of the pandemic in former roles as Director of Research, Medical and Innovation at the ABPI, member of DHSC Candidate Prioritisation Groups and Chair of FPM policy and communications group. Sheuli is currently a member of FPM COVID Expert Group and also advises the UK Pandemic Ethics Accelerator.

Sheuli also works on wider life science policy issues which includes the impact of the pandemic on clinical research; this has included advising the UK Clinical Research Recovery, Resilience and Growth Programme Board.

Sheuli is a Global Fellow in Medicine Development with IFAPP. Sheuli holds a number of other roles, including membership of the expert advisory groups for C2-Ai, the NIHR AI for Multiple Long-term conditions (AIM) Programme and the PrinciPILs trial and is the Chief Medical Officer at BloodworksUK.

Sheuli Porkess

Sheuli is a highly experienced and respected leader in life sciences.

Sheuli originally trained in medicine at Cambridge and Oxford then worked in the NHS before moving to pharmaceutical medicine. Sheuli has worked internationally in medical affairs, clinical development and life science policy.

She is the Vice President of the Faculty of Pharmaceutical Medicine, a Fellow of the Royal College of Physicians of London and a Global Fellow in Medicines Development with IFAPP.

Sheuli is a member of the Steering Group for the UKRI Multiple Long-Term Conditions Programme, the AoMRC Genomics Professional Partnerships Group and the UK Pharmacogenetics and Stratified Medicine Network Steering Group.

Sheuli is also a visiting lecturer at King’s College London.

Ian Philp

Dr Ian Philp is the founder of Age Care Technologies (ACT) www.agecaretechnologies.org. ACT is the winner of the 2021 United Nations WSIS prize for innovation in healthy ageing.

Dr Philp holds a Doctorate in Medicine from the University of Edinburgh and was a practicing physician for 35 years in the UK National Health Service, spending eight years an Executive Medical Director.

As Professor of Health Care for Older People at the University of Sheffield, he led teams which won the UK hospital team of the year in the care of older people and the Queen’s Anniversary Prize for Higher Education for research into improving the quality of life of older people.

From 2000-8, he was the National Clinical Director for Older People in England.

Dr Philp was awarded a CBE in the Queen’s birthday honours in 2009 in recognition of his work to improve the lives of older people.

Marcel Gehrung

Marcel holds a PhD in Machine Learning in Healthcare from the University of Cambridge. Marcel was named on the Forbes 30 under 30 list, won the Alexander Fleming Prize from the Gates Foundation for his contribution to global public health and the Prix Galien Award for the best medical technology with Cyted’s core product, a novel test for the early detection of cancer in the oesophagus.

James Fry

James heads Mills & Reeve’s multi-disciplinary life sciences practice. He supports businesses across the full product lifecycle, from start-up to commercialisation.

A key focus of his work is supporting clients on strategic contracting covering technology / IP in and out- licensing transactions, research collaborations, clinical trial agreements and long term partnering agreements. James also advises on sector regulation including pharma and medical device regulation, market access, borderline products, advertising and clinical trials.

Stefan Kulik

Stef Kulik is the Managing Director of Royal Mail Health, which was officially launched in 2022, after many successful years building partnerships in multiple areas of the healthcare ecosystem. Stefan is responsible for the company’s development in the coming years, working across the changing patient, regulatory, treatment and supply chain needs, to help put Royal Mail at the front of making healthcare better for communities across the UK. Stefan’s history is across large corporations, including Johnson & Johnson, as well as a number of technology and AI related start-ups and big data organisations, where he has gained extensive experience in health.

Claire Thompson

Claire is an award-winning scientist, strategist and storyteller with more than 15 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations. She is CEO of Agility Life Sciences, an award-winning CDMO, consulting and communications firm which works with organisations across the healthcare space to advance their products and raise their profile. She is also Entrepreneur in Residence at the University of Cambridge, and holds an Honorary Professorship from the School of Pharmacy at the University of Nottingham. Claire is Chair of the International Pharmaceutical Federation’s Women in Science and Education (FIP WiSE) initiative.

Steve Barr

Steve has 28 years’ experience in the Pharma and CDMO space. Following completion of a PhD in Organic chemistry at the University of Glasgow, Steve spent his early career working with large pharma in a range of technical and operational roles. He then moved into strategic sourcing and procurement before moving into Business development. Over the last 15 years Steve has worked with a variety of leading CDMO’s, taking progressive senior commercial responsibilities.

He joined SK in June 2018.

Steven Facer

Steve is currently the Vice President of Business Development , Europe/ ROW at Adare Pharma Solutions.

With 25 years of pharmaceutical and biotech industry experience, Steve has expertise in successfully leading CDMO businesses in developed and emerging markets resulting in strong top and bottom line growth and customer satisfaction.

Prior to joining Adare , Steve held senior commercial and operations positions with various Pharma Products and Service organizations, including Thermo Fisher Scientific, Catalent, Capsugel and Colorcon. He has a Honours Degree in Materials Science and Technology from University College Swansea , Wales.

Chris Davison

Experienced Technical Director with extensive experience of working a in the pharmaceuticals industry.

I am expert in pharmaceutical development, manufacturing science and technology with a consistent track record of delivering high quality and robust medicines. I am experienced in Quality by Design, regulatory submissions and technology transfer.

I am an accomplished leader of technical functions and matrix teams across both Manufacturing and R&D organisations. I ensure success by setting the vision and develop strategies aligned to the organisations ambition, focusing on internal and external collaboration to deliver value.

As a leader of both line and matrix teams I have a people centric approach, setting high standards and driving delivery, whilst also creating an environment focused on personal development and continuous improvement to ensure everyone fulfils their potential.

Kathryn Simpson

Kathryn is a respected and successful change leadership expert, with diverse career experience in Europe and North America. She has over 25 years of consulting and line experience with leading organisations (Unilever, Mars, KPMG and GSK). Since 2007 she has been leading her own independent consulting business, primarily working within the Life Sciences sector. By partnering with leaders at all levels within the sector, growth and sustainable success has resulted for the organisations she has worked with. She has recently published a book – “Leading for Change: How to thrive during uncertain times”.

She provides each organisation the approaches they need to meet their unique situation. Tailored approaches are used to develop a consolidated understanding of their environment and the priority challenges they face. This provides the basis for facilitating customised workshops where leaders not only create a desired future, but are ready to move forward and implement their ideas. Working with individual leaders or teams she advises how to bring other stakeholders with them so they achieve success together. These practical and supportive approaches create focus, accountability and collaboration across organisations and their partners. Organisations are left with an increased leadership capability and tangible business results.

Amina Udechuku

Dr Amina Udechuku is currently the Commercial Head of Vaccines, UK and started with Takeda UK as the ‘Head of Appraisals & Centre of Excellence’ in the Market Access and Pricing team at the beginning of 2020. Amina has historically co-led the UK Gender Parity Network Employee Resource Group and represented the UK on the regional Europe & Canada Diversity Equity & Inclusion (DE&I) council. In 2020, Amina established and has since co-led the UK & Ireland DE&I Council.

Amina holds a BSc in Psychology, and a PhD in Epidemiology with her thesis on ‘Demographic and modifiable risk factors in age related cognitive impairment’, both from Loughborough University.

Joshua Blight

Josh has a PhD in Vaccinology and Infectious Diseases from the Jenner Institute at the University of Oxford where he pioneered computational approaches to design vaccines against various infectious diseases. He’s designed a number of vaccines against diseases such as dengue and chikungunya to human papilloma virus (HPV) and malaria. Two of his vaccine candidates are currently in human clinical trials and licensed to pharma. For the last three years he worked as a postdoctoral research associate at Imperial College London, developing new ways to create malaria vaccines. In 2019 he co-founded Baseimmune to generate mutation-proof vaccines through deep learning technology.

Jane Kennedy

Jane Kennedy joined Discovery Park as Chief Business Officer in June 2021. Her remit is to drive strong business growth through the strategic development of the 220 acre science park; building an innovation hub, fostering a collaborative community on site and driving knowledge exchange.

With a Communication Studies degree, Jane spent the early part of her career working in advertising and marketing. In 2005 she became Marketing Manager of Roslin Biocentre (famed as the home of Dolly the sheep, the world’s first cloned mammal) running the science park and learning about the needs of startup and growing life sciences companies.

As the first employee of BioCity Scotland, she was instrumental in converting an ex-pharma site into BioCity’s first venture outside of Nottingham, launching and co-chairing the Glasgow BioCorridor. Additionally she launched the University of Glasgow’s Clinical Innovation Zone – a centre built around Stratified Medicine and Imaging – at the Queen Elizabeth University Hospital.

Jane has held several Startup support roles assisting early-stage tech-based businesses to build their teams and attract investment. She lives just outside Edinburgh in Scotland and splits her time working from home and travelling to the Discovery Park site in Sandwich, Kent.

Fiona Marston

Fiona is a biotechnology entrepreneur who has worked in the industry for >25 years and currently is Chair and CEO of Erebagen Limited a synthetic biology company with a technology platform for pharma discovery and development. She previously founded and developed biotech businesses notably Novacta Biosystems.

From 2018-2023 Fiona worked for Liverpool School of Tropical Medicine (LSTM) as Director of the Centre of Excellence in Infectious Diseases Research focused on commercial translation for the LSTM and University of Liverpool  and subsequently as Royal Society Entrepreneur in Residence supporting training and mentoring in commercial translation for staff and students.  Early in her career Fiona worked in international business development and went on to found an investment incubator Healthcare Ventures, for the Rothschild Bioscience Unit and J&J Development Corporation investing in European entrepreneurs.

Fiona recently was appointed Royal Society Entrepreneur in Residence for the University of Reading. She also advises the seed fund UKI2S and the NC3R’s CRACK IT Challenge, is a Bruntwood SciTech Life Sciences Mentor and a Non-Executive Director for Alder Hey NHS Foundation Trust.

Fiona has a BSc Hons (Biological Sciences; UEA), PhD (Biochemistry; UKC), MBA (London Business School) and was awarded an OBE in the 2021 Queen’s Birthday Honours.

Martino Picardo

Martino is Chairman of Discovery Park and an Independent Consultant, based in
Manchester. From June 2011- July 2017, Martino was the first CEO of the Stevenage
Bioscience Catalyst an ambitious concept to develop an Incubator and Accelerator,
followed by a world class Science Park for the Life Sciences sector Having been
CEO at Stevenage Bioscience Catalyst, Martino was recently Entrepreneur in
Residence at UMIP, Manchester (2017-2020) and was working part-time with the
NHS in Manchester, also as an Entrepreneur in Residence.

Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at
Baylor College of Medicine, Houston, TX in Cardiovascular research. Martino joined
Amersham International in 1991 and subsequently went on to manage the R&D
Technology Transfer Group, based in Cardiff and developing high throughput
screening technologies for the Pharmaceutical sector.

Following the merger of Amersham with Pharmacia Biotech, Martino became the
Science Director for the Cardiff site, Martino then became a Business Manager for
Manchester Biotech Ltd. and subsequently Manchester Innovation Ltd. in June 1999.
When the Universities of Manchester and UMIST merged, he became Managing
Director of UMIC and MICL and was also a Board member of UKBI (UK Business
Incubation).

Martino has also been a Board member of the Hertfordshire LEP. Most recently,
Martino was appointed to the Board of BIONOW, the Northern member Organization
for Life Sciences, as a non- Executive Director (2018-2023). He is currently
Chairman of Discovery Park Ltd., Vitarka Therapeutics Ltd and Evidential Ltd. He is
also a Director of Discovery Park Ventures.

Suzanne Dilly

Dr Suzy Dilly is currently serving as the Chief Executive Officer of the AIM-listed UK biotech, ValiRx PLC. Suzy is an experienced entrepreneurial scientist. After commercialising her Chemical Biology post-doctoral research in the University of Warwick spin-out, a2sp Limited, Suzy was awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, during which formal commercial and entrepreneurial training completed her transition from lab to boardroom. Completing commercial transactions to progress projects through multiple companies, Suzy has been working in small company virtual biotechs since 2006.

Phil Carvil

For the last couple of years Phil has had the pleasure of working with colleagues and stakeholders in developing High-Tech. regional innovation clusters, in key strategic sectors for the UK. This includes setting up and leading the North West of England’s Health and Life sciences Cluster (HealthTech) and establishing other clusters in sectors such as Space.

The clusters exist to connect key capabilities between stakeholders, national science facilities and innovators in the wider ecosystem to support collaboration, cross-sector innovation and community building.

A scientist by background, he undertook a PhD for the European Space Agency at King’s College London, conducting numerous studies on a SkinSuit which was designed to support astronauts in space and reduce the risk of spinal issues post flight. This has subsequently been used on several astronaut missions.

Passionate about cross sector opportunities, including Health & Space, for 5 years he coordinated the UK’s Space Life and Biomedical Science Association, which among other core activities he led the development of the UK Position Paper ‘Why Space? The opportunity for Health & Life Science Innovation”. He currently chairs the UK’s Regional Space Cluster Advisory board and at a European Level serves as the elected President for the European Low Gravity Research Association (ELGRA).

Jenny Barnett

Jenny is a cognitive neuroscientist and CEO of Monument Tx. She was previously Chief Scientific Officer at Cambridge Cognition where she led clinical trial, healthcare and R&D functions before spinning out Monument in 2021. She has an MA in Experimental Psychology from Oxford University, a PhD in the Epidemiology of Schizophrenia from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She is the author of more than 70 papers, six patents, and two popular science books and is an honorary member of the University of Cambridge Department of Psychiatry.

Oleksandr Gorbenko

Dr Oleksandr Gorbenko is an expert in patient affairs, medical affairs, public health, and community engagement with overall 23 years’ experience in biopharma industry. He graduated as a medical doctor (general practice) in O.Bogomolets’ National Medical University and Shupyk National Healthcare University of Ukraine and later worked on his PhD dissertation in the Ukrainian Institute of Public Health MOH. His experience across pharma includes several medical and commercial roles in representative offices of big biopharma companies (Nycomed/Takeda, Richter Gedeon, GSK) as well as senior global medical roles at GSK and ViiV Healthcare headquarters in the UK. He has an additional experience with UN/UNFPA on community engagement, women empowerment and combating gender-based violence.  Since 2019 Dr Gorbenko has a role of Global Patient Affairs Director at Ipsen with the focus on developing necessary capacities/capabilities cross-functionally, advice-seeking and insights gathering with patient experts throughout the Medicines Development Continuum, patient experience mapping, partnership with several patient organisations, substantiation and inclusion of the specific PRO/PCO measurements as endpoints, defining the patient value attributes within the Target Value Profiles (TVP) for new medicines, KPIs and impact indicators on patient centricity for big pharma and other programmes. Board Certified Medical Affairs Professional (ACMA, 2020) and member of MAPS Focus Area Working Group on Patient Centricity.

Charlotte Harris

A versatile senior technology consultant focused on leading and developing Team’s Front End Innovation service offering and practices – including design research, facilitation, strategy, design sprints and innovation management.
Over 20 years’ experience in medical device product development as an innovation leader, project manager and business developer to significant clients globally resulting in high quality delivery of innovative medical project solutions across the full product development lifecycle.

Brennan Miles

Brennan is an accomplished medical device expert with an extensive background in managing and delivering innovative, high-value programmes across a range of medical technology and pharmaceutical delivery routes. These include infusion, injection, intranasal, implantable, ocular, oral, respiratory and topical applications. He also has hands-on experience of gaining device approval within the regulatory frameworks.

With his direct experience of product development and industry knowledge, Brennan co-ordinates Team Consulting’s drug delivery activities to ensure we continue to create exciting technologies, develop more sustainable medical products and deliver exceptional services for our clients.

Prior to his appointment at Team, Brennan worked on the development of medical devices for a large pharmaco as well as in other sectors for several multi-national companies. Brennan has a BSc (Hons) degree in Product Design and Engineering and is the named inventor on several patents.

Lord James O’Shaughnessy

James is one of the UK’s leading policy advisors. He has operated at the highest levels of government, including as a Minister at the Department for Health & Social Care, as Director of the No.10 Policy Unit, and as an advisor to DHSC Ministers during the COVID-19 crisis. James is driven by the twin goals of bringing life-changing health innovations to patients and growing the UK’s life science & healthtech industries. As Minister his responsibilities included implementing the Life Science Industrial Strategy, delivering a new pricing scheme with the pharmaceutical industry, chairing the National Genomics Board, and driving the digital transformation of the NHS. He was also responsible for preparing the health and social care sectors for Brexit and helping to design the post-Brexit regulatory regime. In 2021 James became co-founder and Senior Partner of Newmarket Strategy, a consultancy dedicated to improving access to health innovation by providing strategic advice and technical support to the healthcare, life sciences and health tech sectors. At Newmarket, James provides senior counsel to multinationals, SMEs, investors, universities, hospitals and charities, with a particular focus on technology, digital and data. He is a Visiting Professor at the Institute of Global Health Innovation at Imperial College, where he chairs the Data, Health & Wealth programme, and a non-executive director of both Health Data Research UK and the Albion Development VCT plc. Outside of health, James chairs the Repairing our Social Fabric programme at the think tank Onward and has a keen interest in education reform.

James Chennells

26 year industry experience across CROs & Pharma working in Clinical Operations, Business Development & Procurement. Following a Biology Degree I started my career as CRA working for Icon before moving into Business Development at Covance and subsequently Kendle (now Syneos). I joined Bayer in 2003 heading up a European Clinical Outsourcing function. As the outsourcing function developed and ultimately moved into the Global Procurement function at Bayer I assumed greater responsibility. These responsibilities have included leading regional teams across Europe & Asia for Pharma Development sourcing activities and Global teams responsible for Pharma Development Category strategy. During this time I have also been heavily involved in the management of key supplier partnerships.

In 2021 I moved into Bayer Clinical Operations to take up my current role leading an agile team to identify and manage a portfolio of future solutions supporting new approaches to clinical trial Planning and conduct to deliver faster, better, cheaper trials.

Richard Vellacott

Richard is co-founder, CEO and Chair of BiologIC Technologies Limited. BiologIC’s integrated processing development platform enhances yields, process robustness and scalability of advanced biology products.  The platform, enabled by novel biocomputer technology, is a new category of machine built from fluidic processing chips designed like computer chips.  Our vision is to help customers engineer biology to solve enormous challenges faced by humanity (feeding 9.8 billion people by 2050, mitigating climate change and reducing the threat of diseases) in an environmentally sustainable, economically accessible way.

An authentic and passionate leader, Richard inspires transformational change through the alignment of purposeful vision, high performing talent and quality capital.  He creates significant value through executive leadership, vision and strategy, commercialisation of science, capital market expertise, cultural and organisational change and building operational scale.

In seven valuable years as interim CEO, deputy CEO, CFO, COO and Company Secretary, Richard was instrumental in growing Horizon Discovery Group plc from an emerging private company of £3m revenue in 2012 to a recognised global leader in gene editing delivering revenue of £60m at a valuation of £350m.  Richard delivered one of the most successful ever Life Science listings on AIM raising £68.6m in a heavily oversubscribed IPO at the top of its valuation range within 3 months, fundraisings in the UK and the US, four acquisitions and hostile bid defence.

Richard was previously Vice President, Finance at CSR plc, a dual listed FTSE 250 semiconductor company with $1bn of revenues, and a director in Deloitte’s life sciences practice.  Richard is a qualified chartered accountant with a first class degree in biological sciences from Durham University.

Christian Jones

Christian is the Chief Commercial Officer for Nanoform and leads the business activities for the company. In his role he works with Pharma and Biotech partners to bring their drug molecules back to life by rapidly improving their solubility and bioavailability through the application of Nanoform’s proprietary solution to nanoparticle technology.
He has a strong track record commercially in Drug Substance (DS) and Drug Product (DP) Development and Manufacturing services, Technology Development and Commercialisation, Sales and Marketing and Strategy Development and Implementation.

Christian has a strong knowledge of the healthcare market with global experience and an ability to quickly understand how best to strategically leverage an organisation’s strength to maximise success. He has experience of working across the pharma value chain from Drug Discovery through to Commercial Manufacturing in a range of organisations including Tripos Discovery Research Ltd, Prosonix Ltd, Dr Reddy’s Laboratories Ltd, Johnson Matthey Plc and now Nanoform Finland Ltd.

Christian is a Chemist by training and graduated from the University of Leeds in 2003 with a Masters of Chemistry Degree. He is also a Fellow of the Royal Society of Chemistry and is passionate about new technologies and scientific innovation and he has a deep technical understanding of Crystallisation Science, Particle Engineering and Respiratory Drug Delivery.

Sam Windsor

Sam is the CEO and Co-Founder of Ignota Labs. Ignota Labs’ Explainable AI platform predicts and solves safety problems throughout the drug development process. Sam is a former mathematician and leader in data-driven solutions to solve healthcare-related problems. He has an MBA from INSEAD Business School, a Masters in Mathematics from Nottingham University and experience working across the NHS, big pharma and other corporates, hospital trusts, and startups.

Nick Smith

An experienced pharmaceutical professional, Nick Smith has held various leadership roles within large and emerging organisations delivering complex programs and driving continuous improvement. Nick has successfully established the operational delivery new manufacturing facilities, extended and increased the productivity of new and mature lines as well as rapid new product introductions most notably the BDS for a COVID vaccine. With a background in Quality, Nick is well versed in delivering solutions that meet GMP requirements.

Tamsin Berry

Tamsin has extensive experience in government and expertise in public policy. As the former Director of the UK government’s Office for Life Sciences she worked with Sir John Bell to write the UK’s Life Sciences Industrial Strategy, which led to £3 billion of investment into UK biotech across a number of public and private partnership projects.
During a successful career as a senior civil servant Tamsin held a number of leadership positions in government, spanning policy, corporate and communications roles including at the Cabinet Office, Department of Health and Public Health England. She began her career in consultancy at Accenture. She studied law at Nottingham University, holds a Masters in Philosophy from the University of Leeds and was a Science and Policy Fellow at University of Cambridge.

Tamsin has recently launched a new partnership venture in the UK and US specialising in population health.